SS Innovations Conducts Interactive Meeting with the Center for Devices and ... - Yahoo Finance
SS Innovations plans to submit its SSi Mantra Surgical Robotic System for FDA approval via a de novo pathway, aiming for clinical trials in Q1 2025 and potential market approval by end of 2025.
Highlighted Terms
Related News
SS Innovations expects FDA approval for its Mantra surgical robot by end of 2025, following feedback from a pre-submission meeting. The company plans to submit for IDE in Q1 2025 to initiate clinical trials for various indications, leveraging ongoing clinical use in India and additional trials in the U.S.
SS Innovations plans to submit the SSi Mantra Surgical Robotic System for FDA approval via a de novo pathway, aiming for pre-market approvals by end of 2025, after conducting clinical trials for various indications including abdominal, pelvis, thoracic, and cardiac surgeries.
SS Innovations plans to submit the SSi Mantra Surgical Robotic System for FDA approval via a de novo pathway, aiming for pre-market approvals by end of 2025, with clinical trials for various indications including cardiac to be conducted in the U.S.
SS Innovations plans to submit its SSi Mantra Surgical Robotic System for FDA approval via a de novo pathway, aiming for clinical trials in Q1 2025 and potential market approval by end of 2025.